Notice2025-19375
Government Owned Inventions Available for Licensing: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 2, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Child Health and Human Development (NICHD), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the inventions listed below, which are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 189 (Thursday, October 2, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 189 (Thursday, October 2, 2025)]
[Notices]
[Page 47784]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-19375]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing: Generating
Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse
Casq2
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Child Health and Human Development
(NICHD), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is giving notice of the
inventions listed below, which are owned by an agency of the U.S.
Government and are available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT: Inquiries related to these licensing
opportunities should be directed to: Heather Gunas, Ph.D., MPH,
Technology Transfer Manager, NCI, Technology Transfer Center, Email:
<a href="/cdn-cgi/l/email-protection#2a4d5f444b59426a474b434604444342044d455c"><span class="__cf_email__" data-cfemail="5037253e312338103d31393c7e3e39387e373f26">[email protected]</span></a> or Phone: 240-276-5534.
SUPPLEMENTARY INFORMATION: Cardiac calsequestrin (Casq2) plays an
essential role in maintaining cardiac Ca\2\\+\ homeostasis. Human CASQ2
mutations are associated with catecholaminergic polymorphic ventricular
tachycardia (CPVT), a rare familial arrhythmogenic disorder within a
group of diseases characterized as Sudden Arrhythmic Death.
The inventors have generated Casq2Flox and Casq2RevFlox mouse
strains that model CPVT. The two novel strains successfully phenocopy
aspects of CPVT, including stress-induced arrhythmias and reduced basal
heart rates. The strains allow investigators to determine the
importance of Casq2 gene function in specific tissues and at specific
developmental time points. They also allow investigators to determine
the efficacy of gene therapy and to address key mechanism questions.
The materials are validated and fully functional and additional
information to access these strains can be found at: <a href="https://www.jax.org/strain/036291">https://www.jax.org/strain/036291</a> and <a href="https://www.jax.org/strain/036290">https://www.jax.org/strain/036290</a>.
This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part
404.
NIH Reference Number: E-128-2024.
Product Type: Research Tool.
Therapeutic Area(s): Rare/Neglected Disease.
Potential Commercial Applications:
<bullet> Study of Casq2 function.
<bullet> Study of calcium storage in cardiac muscle and CPVT.
<bullet> Determining the efficacy of gene therapy for CPVT.
Competitive Advantages:
<bullet> Only available conditional and reverse conditional loss-
of-function alleles in mouse Casq2.
<bullet> Allows the study of Casq2 gene function in specific
tissues and at specific developmental points.
Publication:
<bullet> Knollmann BC, et al. Casq2 deletion causes sarcoplasmic
reticulum volume increase, premature Ca\2\\+\ release, and
catecholaminergic polymorphic ventricular tachycardia. (<a href="https://pubmed.ncbi.nlm.nih.gov/16932808/">https://pubmed.ncbi.nlm.nih.gov/16932808/</a>).
<bullet> Flores DJ, et al. Conditional ablation and conditional
rescue models for Casq2 elucidate the role of development and of cell-
type specific expression of Casq2 in the CPVT2 phenotype. (<a href="https://pubmed.ncbi.nlm.nih.gov/29452352/">https://pubmed.ncbi.nlm.nih.gov/29452352/</a>).
<bullet> Blackwell DJ, et al. The Purkinje-myocardial junction is
the anatomic origin of ventricular arrhythmia in CPVT. (PMID <a href="https://pubmed.ncbi.nlm.nih.gov/34990403/">https://pubmed.ncbi.nlm.nih.gov/34990403/</a>).
Patent Status: N/A.
Development Stage: Discovery.
Collaboration Opportunity: NICHD seeks licensing for further
developing or utilizing these Casq2 mouse strains.
Dated: September 30, 2025.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2025-19375 Filed 10-1-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 2, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.